Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tvardi TherapeuticsLTS:0HTC 18 5-Year Yield-on-Cost % is 0.00 as of Jul. 29, 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 150 Biotechnology companies, Tvardi Therapeutics ranks worse than 666666% on this metric.
Tvardi Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Tvardi Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
LTS:0HTC's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.695 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Tvardi Therapeutics 5-Year Yield-on-Cost % Related Terms
LTS:0HTC vs CRVO, JSPR, SKYE: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Tvardi Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tvardi Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Tvardi Therapeutics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Tvardi Therapeutics (LTS:0HTC) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry.
Is Tvardi Therapeutics' 5-Year Yield-on-Cost % too high?
Tvardi Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Tvardi Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tvardi Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' 5-Year Yield-on-Cost % compare to CRVO and JSPR?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Tvardi Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Tvardi Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tvardi Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Tvardi Therapeutics' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
18GF Score
Get the complete analysis for LTS:0HTC
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTC has been successfully added to your 
